STShin Takayama

Shin Takayama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shin Takayama has a total of 446 co-authors. Here are the top co-authors by number of shared publications:

  • Tadashi Ishii

    Department of Kampo and Integrative Medicine, Tohoku University Graduate School of Medicine

    49 shared publications
  • Akiko Kikuchi

    Department of Kampo and Integrative Medicine, Tohoku University Graduate School of Medicine

    40 shared publications
  • Ryutaro Arita

    Department of Kampo and Integrative Medicine, Tohoku University Graduate School of Medicine

    32 shared publications
  • Nobuo Yaegashi

    Tohoku Univ, Dept Gynecol & Obstet, Grad Sch Med, Sendai, Miyagi, Japan

    22 shared publications
  • Minoru Ohsawa

    Department of Education and Support for Regional Medicine (General and Kampo medicine), Tohoku University Hospital, Sendai, Japan

    21 shared publications
  • Natsumi Saito

    Department of Kampo Medicine, Tohoku University Hospital

    19 shared publications

Latest Publications

  • Open Access

    Correction: Japanese traditional Kampo medicine as a holistic countermeasure for spaceflight-induced physiological and psychological health challenges: a comprehensive review

    by Shin Takayama, Silke Cameron, Kenny Kuchta, Tadashi Ishii, Masahiro Terada

    Providing anti-inflammatory modulation and reducing the production of pro-inflammatory cytokines such as 26,27]."The original version of this article has been updated.

  • Open Access

    A Case of Remarkable Improvement in Dizziness and Lightheadedness in an Elderly Patient Treated With Goshajinkigan

    by Akiko Kikuchi, Rie Ono, Hidehisa Saito, Shin Takayama, Tadashi Ishii


  • Open Access

    Persistent mitochondrial and endothelial dysfunction in non-hospitalized patients with Long COVID

    by Rie Ono, Shin Takayama, Michiaki Abe, Ryutaro Arita, Koh Onodera, Kota Ishizawa, Takeshi Kanno, Natsumi Saito, Akiko Kikuchi, Takaaki Abe, et al.

    Long COVID, a major post-acute infection syndrome (PAIS), characterized by prolonged or new-onset symptoms following acute COVID-19, critically affects patients' quality of life. Establishing easily measurable and objective biomarkers that reflect disease severity is essential for clinical management. This retrospective cohort study evaluated serum levels of growth differentiation factor 15 (GDF-15), a mitochondrial stress marker, and vascular cell adhesion molecule-1 (VCAM-1), a vascular endothelial stress marker, in 32 patients with Long COVID who presented with persistent systemic or neurological symptoms and had not required acute-phase hospitalization. Serum GDF-15, VCAM-1, and inflammatory cytokine levels were measured at the initial visit and at 3 and 6 months. Differences between patients who recovered at 6 months and those who did not (non-improved group) were analyzed using linear mixed-effects models (LMMs). Most inflammatory cytokines remained near their lower detection limits and were excluded from the longitudinal analysis. The LMMs revealed sustained elevation of both GDF-15 ( p = 0.02) and VCAM-1 ( p = 0.03) levels in the non-improved group. These findings suggest that longitudinal tracking of these two markers may offer clinically relevant insights into disease activity and treatment-resistant pathophysiology in mild acute-phase Long COVID.

  • Open Access

    Authors' Reply: Conceptual Translation and Patient Safety in the Cross‐Cultural Transfer of Kampo Medicine

    by Yonatan Klein, Tetsuhiro Yoshino, Yuko Horiba, Yuzo Ishii, Ryutaro Arita, Natsumi Saito, Akiko Kikuchi, Akira Kaneko, Kazushi Uneda, Shin Takayama, et al.

  • Open Access

    Japanese Traditional Kampo Medicine as a holistic countermeasure for spaceflight-induced physiological and psychological health challenges: a comprehensive review

    by Shin Takayama, Silke Cameron, Kenny Kuchta, Tadashi Ishii, Masahiro Terada

    Spaceflight introduces a complex array of health challenges that affect nearly every physiological system, primarily owing to microgravity, cosmic radiation, isolation, altered environments, and logistical supply constraints. Astronauts commonly experience musculoskeletal degradation, including bone density and muscle mass loss; cardiovascular deconditioning; and fluid redistribution. These lead to orthostatic intolerance; immune suppression; increased infection risk; exposure to ionizing radiation, which poses elevated risks of malignancy and neurodegenerative diseases; gastrointestinal dysfunction; gut dysbiosis; and cognitive, psychological, and sleep disturbances. These multifaceted stressors necessitate holistic and multitarget countermeasures, particularly as extended missions have become a reality. Japanese Traditional (Kampo) medicines, composed of multiple herbal ingredients, offer a promising supportive strategy because of their efficacy in simultaneously managing diverse physical and psychological symptoms. Kampo formulas exert diverse benefits. For example, Ninjin’yoeito, Juzentaihoto, Hochuekkito, and Goshajinkigan promote musculoskeletal strength and prevent frailty. Goreisan regulates fluid and cardiovascular homeostasis; Hochuekkito supports immune modulation and infection prevention; Rikkunshito address gastrointestinal symptoms via appetite and digestive regulation; and Yokukansan and Kamikihito mitigate neurological and psychological disturbances. Another benefit is the regulation of the gut microbiota, mitochondrial function, and gene expression, which are relevant to space-induced metabolic and inflammatory alterations. The holistic, preventive, and safe profile of Kampo medicines make them well suited for integrated health management in space, facilitating the maintenance of performance and quality of life during long-duration missions. Ongoing research and advances in personalized medicine will help clarify and optimize the application of Kampo in space medicine.

  • Open Access

    The Journey of Studying Kampo Medicine in Japan Through the Eyes of an Israeli Acupuncturist and Kampo Practitioner

    by Yonatan Klein, Tetsuhiro Yoshino, Yuko Horiba, Yuzo Ishii, Ryutaro Arita, Natsumi Saito, Akiko Kikuchi, Akira Kaneko, Kazushi Uneda, Shin Takayama, et al.

    Objective: To highlight the stark contrasts in the integration, regulation, and practice of traditional medicine between the two countries (Israel and Japan). Methods: This article chronicles the personal and professional journey of an Israeli acupuncturist studying Kampo medicine in Japan. Through personal experience as a visiting researcher at Keio University Hospital, Tohoku University Hospital, and Fukushima Medical University Aizu Medical Center, this paper reports on the observed systematic approach of Kampo, including the diagnostic method of Fukushin (abdominal diagnosis) and discusses the challenges and opportunities for non‐physicians seeking to study this field in Japan. Results: While Traditional Chinese Medicine ( TCM ) in Israel is primarily practiced in private clinics with limited governmental regulation, Kampo medicine in Japan is formally integrated into the national healthcare system, covered by insurance, and taught in all medical schools. Additionally, the clinical utility of Fukushin was observed, and significant challenges for non‐physicians studying Kampo in Japan were identified. Conclusion: The author's journey underscores the institutional legitimacy of Kampo and suggests a path toward fostering a greater exchange between Israeli TCM and Japanese Kampo, bridging two traditions that are similar in origin yet vastly different in their modern application and recognition. To address the challenges for non‐physicians, establishing short‐term clinical observation programs is proposed as a concrete solution.


  • Open Access

    Factors involved in the improvement of prolonged symptoms in patients with COVID-19 treated with Japanese traditional (Kampo) medicine: A single-center, prospective, observational study

    by Tsuyoshi Kawamura, Junko Kohno, Akiko Kikuchi, Ryutaro Arita, Shin Takayama, Tadashi Ishii

    Patients with prolonged symptoms of COVID-19 (PSC) show various symptoms, especially fatigue, which affect their activities of daily living and inhibit their return to social life. As there is no standard treatment for PSC, we developed a treatment regimen that includes Japanese traditional (Kampo) medicine according to patient symptoms and condition. This study aimed to investigate the progression of symptoms in patients with PSC using this treatment regimen and to assess differences in background factors that affect the improvement of symptoms in patients. We conducted a prospective, observational study and collected data from patients with PSC who visited a hospital in Japan between May 2022 and December 2023. The patient performance status (PS, 0–9) and 16 symptoms on a numerical rating scale (NRS, 0–10) were recorded at each visit. A total of 114 patients were analyzed. The group with a first visit general fatigue score equal to or greater than the median (GMGF group) took more time to achieve PS ≤ 2 (hazard ratio [95% confidence interval (CI)], 0.405 [0.253–0.650], P < .001) and the end of visit milestone (0.283 [0.150–0.532], P < .001) compared to the group with a first visit general fatigue score less than the median (LMGF group). The group with ≥90 days from the onset to the first visit (≥90 days group) reached the end of visit milestone significantly later (0.510 [0.267–0.974], P = .041) than the group with P < .001) and 0.148 (0.058–0.380, P < .001), respectively. The ≥90 days group experienced difficulty in achieving the end of visit milestone within 3 months of the first visit (odds ratio [95% CI], 0.430 [0.179–1.035], P = .06). Patients with PSC who have a high general fatigue score at their first visit may have difficulty improving their symptoms. Early treatment, including Kampo medicine, can promote the improvement of PSC symptoms.

  • Open Access

    Evaluation of Treatment Outcomes in Kampo Outpatients Using an Electronic Questionnaire and Development of Predictive Algorithms: A Protocol of Observational Study

    by Tetsuhiro Yoshino, Tomonori Nakamura, Seiya Imoto, Shin Takayama, Tatsuya Nogami, Hidenori Ito, Eiichi Tahara, Kazuhisa Kaneda, Takao Namiki, Koichi Fukunaga, et al.

    Introduction: This study aims to evaluate treatment outcomes in Kampo outpatients using electronic questionnaires by accumulating multi‐institutional data. It also aims to improve algorithms for predicting traditional pattern diagnosis and create algorithms for prescribed formulas and subjective symptom changes. Methods: This multi‐center observational study involves adult patients visiting Kampo outpatient clinics in Japan. Data will be collected from patient electronic questionnaires, physicians' entries into an Electronic Data Capture system (Kampo/Western diagnoses and prescriptions), and medical records including medical history, concomitant medications, and routine blood/urine test results. The primary outcome is the change in Visual Analogue Scale (VAS) scores for the chief complaint. Secondary outcomes involve developing predictive models for VAS changes, pattern diagnosis, and formula prescription. Statistical analyses will be performed using R‐software. Missing data will generally be handled by excluding cases lacking essential items. Outliers will be addressed through sensitivity analyses performed both with and without exclusion. Anticipated Results: The study will yield predictive algorithms for pattern diagnosis, formula selection, and subjective symptom changes. Performance metrics such as accuracy, precision, sensitivity, specificity, and F‐measure will be reported for the models. Conclusion: This study aims to contribute to the appropriate use of Kampo medicine by developing clinical support systems through the creation and improvement of predictive algorithms. The findings are expected to enable efficient and safe healthcare delivery in clinical settings. Trial Registration: The study is registered with the University hospital Medical Information Network (UMIN‐CTR). Registration No.: UMIN000042048


  • Open Access

    Retrospective observational study of Kampo medicines for suppressing the side effects of endocrine therapy in the treatment of breast cancer: a pilot study

    by Shin Takayama, Atsuhiko Furuta, Haruhiko Shindo, Ryutaro Arita, Kaolu Sato, Tadashi Ishii

    Background: Long-term endocrine therapy for breast cancer often causes menopause-like symptoms, affecting quality of life. Although Japanese traditional (Kampo) medicine is utilized for relief, research remains limited. Objective: This retrospective observational study aimed to evaluate the efficacy of Kampo medicines in managing endocrine therapy-related side effects in breast cancer patients. Methods: Data from breast cancer patients receiving endocrine therapy treated with Kampo medicines at Japanese Red Cross Ishinomaki Hospital between July 2017 to June 2024 were analyzed. Symptom severity was measured using a Numerical Rating Scale (NRS; 0–10). Kampo medicine, administered by a specialist, was tailored to individual symptoms and physical findings. Multivariate analysis was performed to examine the association between symptom relief. Symptom progression was analyzed using Kaplan-Meier curves, and outcomes were compared using the log-rank test. Results: Fifty-three patients (median age: 54) were enrolled. Vasomotor, motor/sensory, and psychiatric symptoms accounted for 90% of complaints. After 6 months, 75% of patients reported NRS scores of 3 or less (enabling them to perform daily activities without difficulty). Keishibukuryogan (KBG) or keishibukuryogankayokuinin (KBGY) were the most prescribed (41.5%). Multivariate analysis indicated KBG/KBGY was significantly associated with symptom relief (Hazard Ratio 4.18; 95% CI 1.03–16.92; p = 0.046). Patients prescribed KBG/KBGY experienced significantly faster overall symptom improvement than those on other Kampo medicines ( p = 0.022). Conclusion: Kampo medicines are effective in alleviating side effects in breast cancer patients undergoing endocrine therapy. KBG/KBGY has shown promise in reducing overall symptoms.

  • Open Access

    Integrative strategy for Long COVID neuropsychiatric symptoms: A case report on Kamikihito and Bupleurum-Scutellaria formulas guided by pharmacological rationale

    by Rie Ono, Ryutaro Arita, Shin Takayama, Akiko Kikuchi, Chika Akaishi, Tadashi Ishii